Creating clinical value through meaningful innovation
At Quirem Medical we believe treatment outcome of unresectable liver cancer with SIRT can be improved by using microspheres that can be visualized and quantified to improve patient selection, planning and treatment verification. Will you join us in developing and commercializing the next-generation SIRT microspheres?
Chief Executive Officer
Jan Sigger held senior management positions at Royal Dutch Shell and Akzo Nobel before joining Nucletron, the global market leader in brachytherapy as CFO in 2008. Between 2008 – 2012 he was instrumental in transforming Nucletron into the fastest growing radiotherapy company and managed the sale from private equity ownership to Elekta AB in 2011. Jan Sigger is a Master in Business Economics and holds a post-graduate degree as Chartered Accountant.
Chief Scientific Officer
Frank Nijsen has performed research into Holmium microspheres for more than 20 years. He has led the successful valorisation of the Holmium technology and was instrumental in the creation of the spin-off company Quirem Medical. He holds as inventor many patents in the field. Frank Nijsen holds a doctorate in Medical Biology and is currently Associate Professor at the Radboud University Medical Center.
Member of the Board
Peter Coenen has more than 25 years of experience in the medical device area leading and adapting organizations to new market situations to deliver value to customers and the companies he worked for. Peter started his career in the medical device division of Ely Lilly which then became Guidant. After the acquisition of Guidant by Boston Scientific Peter was responsible for the legal merger of Guidant and BSX in Japan. He today is a Director and Board member in Terumo Europe responsible for the EMEA region as President of the Interventional business unit.
Tim Irish has worked in the life sciences industry for thirty years. His career has spanned global health technology companies across Europe and North America, including GSK, GE and Philips. Tim’s current governance portfolio covers Life Sciences, Healthcare and Education, both public and private, including Board roles as Senior Independent Director and NED at National Institute for Health and Care Excellence (NICE), various European MedTech Supervisory Board roles, and Professor of Practice at King’s College London’s School of Management and Business.
Member of the Board
Paul Roos is a seasoned executive with extensive experience and a proven track record in the international life sciences industry, having spent over 10 years working in investment banking and over five years as a CFO. He currently serves as CFO of Polyganics. Previously Mr. Roos served as CFO of IRX Innovations and as CFO of Synthon. He began his career at the Corporate Finance Division of Kempen & Co, where he his final position was Executive Director in the Life Sciences/ Healthcare team.